These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

559 related articles for article (PubMed ID: 23253319)

  • 21. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin.
    Al-Nassir WN; Sethi AK; Nerandzic MM; Bobulsky GS; Jump RL; Donskey CJ
    Clin Infect Dis; 2008 Jul; 47(1):56-62. PubMed ID: 18491964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The changing face of Clostridium difficile: what treatment options remain?
    Shen EP; Surawicz CM
    Am J Gastroenterol; 2007 Dec; 102(12):2789-92. PubMed ID: 18042108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Fidaxomicin versus vancomycin for Clostridium difficile infection.
    Louie TJ; Miller MA; Mullane KM; Weiss K; Lentnek A; Golan Y; Gorbach S; Sears P; Shue YK;
    N Engl J Med; 2011 Feb; 364(5):422-31. PubMed ID: 21288078
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection.
    Crawford T; Huesgen E; Danziger L
    Am J Health Syst Pharm; 2012 Jun; 69(11):933-43. PubMed ID: 22610025
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The evolution of urban C. difficile infection (CDI): CDI in 2009-2011 is less severe and has better outcomes than CDI in 2006-2008.
    Feuerstadt P; Das R; Brandt LJ
    Am J Gastroenterol; 2014 Aug; 109(8):1265-76. PubMed ID: 25001255
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical approach to severe Clostridium difficile infection: update for the hospital practitioner.
    Pant C; Sferra TJ; Deshpande A; Minocha A
    Eur J Intern Med; 2011 Dec; 22(6):561-8. PubMed ID: 22075280
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fidaxomicin for the treatment of Clostridium difficile infections.
    Whitman CB; Czosnowski QA
    Ann Pharmacother; 2012 Feb; 46(2):219-28. PubMed ID: 22318930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of recurrent and severe Clostridium difficile infection.
    Keller JJ; Kuijper EJ
    Annu Rev Med; 2015; 66():373-86. PubMed ID: 25587656
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options.
    Lo Vecchio A; Zacur GM
    Curr Opin Gastroenterol; 2012 Jan; 28(1):1-9. PubMed ID: 22134217
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clostridium difficile infection.
    Kelly CP; LaMont JT
    Annu Rev Med; 1998; 49():375-90. PubMed ID: 9509270
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027.
    Pépin J; Valiquette L; Gagnon S; Routhier S; Brazeau I
    Am J Gastroenterol; 2007 Dec; 102(12):2781-8. PubMed ID: 17900327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection.
    Citron DM; Babakhani F; Goldstein EJ; Nagaro K; Sambol S; Sears P; Shue YK; Gerding DN
    Anaerobe; 2009 Dec; 15(6):234-6. PubMed ID: 19755166
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Can we identify patients at high risk of recurrent Clostridium difficile infection?
    Kelly CP
    Clin Microbiol Infect; 2012 Dec; 18 Suppl 6():21-7. PubMed ID: 23121551
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recurrent Clostridium difficile infection: a review of risk factors, treatments, and outcomes.
    Johnson S
    J Infect; 2009 Jun; 58(6):403-10. PubMed ID: 19394704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Fidaxomicin--the new drug for Clostridium difficile infection.
    Vaishnavi C
    Indian J Med Res; 2015 Apr; 141(4):398-407. PubMed ID: 26112840
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New and emerging therapies in treatment of Clostridium difficile infection.
    Goyal H; Perisetti A; Rehman MR; Singla U
    Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):589-597. PubMed ID: 29521664
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clostridium difficile Diarrhea in the Elderly: Current Issues and Management Options.
    Mizusawa M; Doron S; Gorbach S
    Drugs Aging; 2015 Aug; 32(8):639-47. PubMed ID: 26233437
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of continued antibacterial therapy after diagnosis of hospital-onset Clostridium difficile infection: implications for antimicrobial stewardship.
    Harpe SE; Inocencio TJ; Pakyz AL; Oinonen MJ; Polk RE
    Pharmacotherapy; 2012 Aug; 32(8):744-54. PubMed ID: 23307522
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Fidaxomicin: a new macrocyclic, RNA polymerase-inhibiting antibiotic for the treatment of Clostridium difficile infections.
    Poxton IR
    Future Microbiol; 2010 Apr; 5(4):539-48. PubMed ID: 20353295
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of increased colonization with vancomycin-resistant enterococci during preferential use of vancomycin for treatment during an outbreak of healthcare-associated Clostridium difficile infection.
    Miller M; Bernard L; Thompson M; Grima D; Pepin J
    Infect Control Hosp Epidemiol; 2010 Jul; 31(7):710-5. PubMed ID: 20518636
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.